Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2021-01-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于SAL0104胶囊临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for a drug named SAL0104 Capsule by the National Medical Products Administration. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, and no detailed report or presentation. The document is an announcement of a regulatory event related to drug development, not a financial report or management information. It is a regulatory announcement informing investors about the acceptance of a clinical trial application and the associated risks. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-01-14 Chinese
公司及华英证券有限责任公司关于公司非公开发行A股股票申请文件二次反馈意见的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed application and response to regulatory feedback regarding a non-public issuance of A shares by Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes extensive financial and project investment details related to clinical research and development projects, with specific funding amounts, project phases, and comparisons to industry peers. The content is focused on the company's capital raising and use of proceeds for R&D projects, including detailed investment calculations and justifications. This aligns with a Capital/Financing Update, as it pertains to fundraising activities and the allocation of raised capital. The document is lengthy (15,000 characters) and contains substantive financial and project data, not merely an announcement or a brief summary. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-01-13 Chinese
关于非公开发行股票申请文件二次反馈意见回复的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the company's response to a second round of feedback from the China Securities Regulatory Commission (CSRC) concerning a non-public stock issuance application. It mentions the company's compliance with disclosure requirements and the ongoing approval process by the regulatory authority. The document is short (670 characters) and serves as an update on the regulatory review process rather than containing detailed financial data or the actual application documents. It is an announcement related to capital raising activities but does not provide substantive financial statements or detailed financing terms. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the status of a financing activity (non-public stock issuance).
2021-01-13 Chinese
关于收到《中国证监会行政许可项目审查二次反馈意见通知书》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding receipt of a second feedback notice from the China Securities Regulatory Commission (CSRC) related to the administrative approval process for a non-public stock issuance. It states the company must respond within 30 working days and that the issuance is subject to CSRC approval, with uncertainty about approval outcome. The document is short (635 characters) and serves as a regulatory update on the status of a capital raising approval process, not the actual financing report or detailed financial data. It is an official regulatory announcement about the administrative review process and related compliance, fitting the category of Regulatory Filings (RNS) as it does not contain financial statements or detailed report data, nor is it a full capital/financing update report.
2021-01-12 Chinese
关于医疗器械临床试验备案的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1222 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the clinical trial filing for a medical device (a rapamycin drug-eluting coronary balloon catheter). It contains no financial data, no detailed financial statements, and no comprehensive report content. It is an announcement of a regulatory filing related to clinical trial approval and does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it does not mention any report being published or attached. The content is regulatory in nature, disclosing clinical trial filing information to investors. Therefore, the best fitting category is Regulatory Filings (RNS).
2021-01-12 Chinese
关于阿利沙坦酯吲达帕胺缓释片获得临床试验受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (885 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for a new drug by the National Medical Products Administration. It contains no financial data, no detailed report, and no mention of financial results or management changes. It is an official regulatory announcement about a clinical trial acceptance, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like Annual Report, Earnings Release, or Capital Update. The document is not a report itself but an announcement of regulatory approval acceptance.
2021-01-10 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.